Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer.
CMO Kemwell is receiving technical assistance from Boehringer Ingelheim for the construction of its new biotech facility, which is designed to marry European technology with Indian low cost manufacturing.
There have been a few changes in the top ten employers according to
leading journal Science's annual survey of the best
companies to work for in the biotech, biopharma, pharmaceutical and